Pharmaxis Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
51,818.00
18,466.00
16,463.00
18,346.00
6,428.00
Depreciation, Depletion & Amortization
14,153.00
3,645.00
3,265.00
3,058.00
3,111.00
Other Funds
-
-
267.00
227.00
-
Funds from Operations
28,759.00
20,753.00
13,832.00
14,636.00
12,073.00
Changes in Working Capital
627.00
1,027.00
1,843.00
626.00
133.00
Net Operating Cash Flow
28,132.00
21,780.00
11,989.00
15,262.00
12,206.00
Capital Expenditures
347.00
266.00
1,383.00
723.00
886.00
Sale of Fixed Assets & Businesses
34.00
2.00
2.00
-
2.00
Net Investing Cash Flow
313.00
264.00
1,381.00
723.00
884.00
Issuance/Reduction of Debt, Net
1,357.00
1,791.00
1,447.00
1,494.00
1,544.00
Net Financing Cash Flow
1,357.00
1,791.00
1,714.00
1,721.00
1,753.00
Net Change in Cash
29,761.00
19,956.00
14,929.00
17,705.00
9,569.00
Free Cash Flow
28,349.00
21,536.00
13,361.00
15,575.00
11,366.00
Exchange Rate Effect
41.00
231.00
155.00
1.00
-

About Pharmaxis

View Profile
Address
20 Rodborough Road
Sydney New South Wales (NSW) 2086
Australia
Employees -
Website http://www.pharmaxis.com.au
Updated 07/08/2019
Pharmaxis Ltd. operates as a specialty pharmaceutical company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. It operates through the following segments: Bronchitol and Aridol Business and New Drug Development. The Bronchitol and Aridol Business segment covers the ongoing clinical development, manufacture, and sale of the Bronchitol and Aridol globally.